We use cookies for a better user experience. Read our Privacy Policy

I Agree

Vaccine Market

Vaccine Market (Human Vaccines: Hepatitis, Influenza, Meningococcal, Pneumococcal, HPV, Combination Vaccines; Animal Vaccines: Canine, Feline, Porcine, Bovine, Ovine, Poultry and Equine) - U.S. Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

The global vaccine market is expected to expand at a visibly fast pace in the years to follow. The need for immunizing people from several types of diseases and infections has created fresh opportunities for growth within the global market. Vaccines are developed after a rigorous process of testing and analysis, and are even tested for several years. The post-trial stage of vaccines is the most critical phase which decides on the success and adoption rate of the newly-developed antigen. The presence of a seamless medical research sector has created humongous demand within the global vaccine market. The need for preventing people from measles, malaria, polio, and other diseases has given an impetus to the growth of the market.

  • The growth of the global vaccine market over the next decade shall be defined by developments in the field of Covid-19 management. The outbreak of the novel coronavirus has taken the medical and healthcare industries by storm, and has created humongous opportunities for market growth and maturity. However, there has been little success in developing vaccines against the virus. Investments in medical research and diagnosis shall create fresh opportunities for expansion across the global vaccines market. The medical industry is currently testing available vaccines against the coronavirus. There has been some success in averting the virus with the help of existing vaccines.
  • Several research laboratories have ramped up their vaccine development budget to expedite the process of Covid-19 management and research. Government have prioritized the development of new research labs and facilities that will focus on developing vaccines against the coronavirus. Countries such as China and the US are expected to invest in new testing and research facilities for Covid-19 management. There is little doubt that the global vaccines market could clock in humongous revenues due to the outbreak of the coronavirus disease.

U.S. Vaccine Market: Snapshot

The overall vaccine industry has strengthened itself in terms of its growth rate, with a relatively higher growth rate than most other healthcare market segments. Vaccination has been an invaluable addition to better public health, and has helped millions of children, adults and animals from deadly diseases. The CDC stated in a report that diseases such as diphtheria, polio, and smallpox have been fully eliminated, while measles, tetanus, and rubella are some of the disease that have been greatly controlled within the U.S., through timely administration of vaccines. Thus, vaccination is considered as the most effective form of all preventive measures.

The U.S. vaccine market is projected to expand at a CAGR of 4.3% from 2014 to 2020.

Education and Awareness Bode Well for Vaccination Rates

The U.S. human vaccine market is expected to expand swiftly owing to drivers such as the lowered risk of serious and fatal side effects with vaccination, increasing awareness regarding vaccination among common people as well as healthcare providers, federal government’s strict recommendations for immunization against certain diseases, and growing demand for adult vaccines. Similarly, the U.S. animal vaccine market is likely to be propelled by the rising incidence rates of zoonotic diseases and the growing risk factor of animal to human transfer of diseases and infections. The rate of pet adoptions is also rising, especially in urban locations, along with a growth in the consumption rate of poultry products and meat. Over the recent past, a number of remarkable animal vaccines have made it through the pipeline and past approvals, including Once PMH IN and Prime Pac PRRS+ further improving the growth rate of this market.

However, increasingly strict guidelines and regulations for the lengthy and time consuming approval process has resulted in the increase in cost of several new vaccines. The development efforts on future pipeline vaccines is also slowing down due to the high costs of development, thereby restraining the U.S. human vaccine market. The manufacturers and distributors of both human and animal vaccines also face the issues related to storage, handling, and transportation of vaccines. Manufacturers require heavy usage of cold storage chains for over 90% of all vaccines currently produced, in order to prevent loss of potency and efficacy by exposure to higher temperatures, considerably increasing the costs of transportation and equipment maintenance.

Pneumococcal Vaccines to Top Charts Till 2020

The U.S. human vaccine market can be classified into pediatric and adult vaccines, in terms of the type of vaccines. Based on antigens, the U.S. human vaccine market has been categorized into hepatitis, influenza, meningococcal, pneumococcal, human papillomavirus (HPV), combination vaccines and others. Among these, combination vaccines market had represented the leading antigen segment in human vaccines for 2013, based on revenue generation.

The animal vaccines market in the U.S. have been segmented into livestock and companion vaccines. The latter segment is further categorized into canine and feline, while livestock vaccines segment can be been segmented into ovine, poultry, porcine, bovine, and equine. Canine vaccines took a relatively larger share than the feline vaccines in 2013, in terms of revenue, due to the higher average cost of canine vaccinations.

The U.S. human vaccine market is dominated by players such as GlaxoSmithKline PLC, Sanofi, Pfizer, Ltd., Merck & Co., Inc., and Novartis International AG. These players have successfully cornered critical areas of the market through the introduction of innovative vaccines and new ones in the pipeline. Zoetis, Inc., Merck & Co., Inc. (Merck Animal Health), Sanofi (Merial, animal health division of Sanofi) and Boehringer Ingelheim are the key companies in the U.S. animal vaccine market.

Vaccine Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

 
Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Assumptions
      1.3.2 Sources
              1.3.2.1 Secondary Research
              1.3.2.2 Primary Research
      1.3.3 Models
 
Chapter 2 Executive Summary
2.1 Market Snapshot: U.S. Vaccine Market (2013 & 2020)
2.2 U.S. Human Vaccine Market, by Antigen, 2013 (USD Million)
 
Chapter 3 U.S. Vaccine Market Overview
3.1 Introduction
3.2 Vaccine Approval Regulatory Pathway
      3.2.1 Major Steps: Vaccine Development and Commercialization
3.3 Drivers
      3.3.1 Growing incidence of zoonotic diseases drives increased animal vaccination
      3.3.2 Increasing consumption of chicken to augment the demand of poultry vaccines in the U.S.
      3.3.3 Extremely low risk of serious and fatal side effects associated with vaccines is a strong driver in the adoption of vaccines
      3.3.4 Education and awareness through various governmental and non-profit organizations
3.4 Restraints
      3.4.1 Strict regulatory pathway and high cost associated with new vaccine discovery and development
      3.4.2 High cost associated with vaccine transportation, storage and handling
3.5 Opportunities
      3.5.1 DNA vaccines hold immense potential for a number of human and animal diseases
      3.5.2 The U.S. offers immense potential for adult vaccines market
3.6 Competitive Landscape
      3.6.1 U.S. Human Vaccine Market Share Analysis, by Key Players, 2013 (Value %)
      3.6.2 U.S. Animal Vaccine Market Share Analysis, by Key Players, 2013 (Value %)
 
Chapter 4 U.S. Human Vaccine Market Revenue
4.1 Overview
      4.1.1 U.S. Human Vaccine Market Revenue, by Type, 2012 – 2020 (USD Million)
      4.1.2 U.S. Human Vaccine Market Revenue, by Antigen, 2012 – 2020 (USD Million)
      4.1.3 Comparative Analysis: U.S. Human Vaccine Market Revenue, by Antigen, 2013 & 2020 (Value %)
      4.1.4 Hepatitis
              4.1.4.1 U.S. Hepatitis Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.5 Influenza
              4.1.5.1 U.S. Influenza Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.6 Meningococcal 
              4.1.6.1 U.S. Meningococcal Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.7 Pneumococcal
              4.1.7.1 U.S. Pneumococcal Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.8 Human Papillomavirus (HPV)
              4.1.8.1 U.S. Human Papillomavirus Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.9 Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV)
              4.1.9.1 U.S. Combination Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.10 Others
               4.1.10.1 U.S. Other Vaccine Market Revenue, 2012 – 2020 (USD Million)
4.2 Pricing Analysis
      4.2.1 Pricing Analysis: Hepatitis Vaccines
      4.2.2 Pricing Analysis: Influenza Vaccines
      4.2.3 Pricing Analysis: Meningococcal Vaccines
      4.2.4 Pricing Analysis: Pneumococcal Vaccines
      4.2.5 Pricing Analysis: Human Papillomavirus Vaccines (HPV)
      4.2.6 Pricing Analysis: Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV)
      4.2.7 Pricing Analysis: Other Vaccines
 
Chapter 5 U.S. Animal Vaccine Market Revenue, 2012 – 2020 (USD Million)
5.1 Overview
      5.1.1 U.S. Animal Vaccine Market Revenue, by Animal Type, 2012 – 2020 (USD Million)
      5.1.2 Comparative Analysis: U.S. Animal Vaccine Market Revenue, by Animal Type, 2013 & 2020 (Value %)
5.2 Companion Animal Vaccines
      5.2.1 U.S. Companion Animal Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million)
      5.2.2 Canine Vaccines
              5.2.2.1 U.S. Canine Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.2.2.2 Pricing Analysis: Canine Vaccines
      5.2.3 Feline Vaccines
              5.2.3.1 U.S. Feline Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.2.3.2 Pricing Analysis: Feline Vaccines
5.3 Livestock Vaccines
      5.3.1 U.S. Livestock Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million)
      5.3.2 Porcine Vaccines
              5.3.2.1 U.S. Porcine Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.3.2.2 Pricing Analysis: Porcine Vaccines
      5.3.3 Bovine Vaccines
              5.3.3.1 U.S. Bovine Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.3.3.2 Pricing Analysis: Bovine Vaccines
      5.3.4 Ovine Vaccines
              5.3.4.1 U.S. Ovine Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.3.4.2 Pricing Analysis: Ovine Vaccines
      5.3.5 Poultry Vaccines
              5.3.5.1 U.S. Poultry Vaccine Market Revenue, 2012 – 2020 (USD Million)
      5.3.6 Equine Vaccines
              5.3.6.1 U.S. Equine Vaccine Market Revenue, 2012 – 2020 (USD Million)
              5.3.6.2 Pricing Analysis: Equine Vaccines
 
Chapter 6 Recommendations
6.1 Focus on cost-effective vaccine manufacturing
6.2 Focus on developing technologically advanced vaccines such as DNA vaccines
 
Chapter 7 Company Profiles
7.1 Boehringer Ingelheim
      7.1.1 Company Overview
      7.1.2 Financial Overview
      7.1.3 Product Portfolio
      7.1.4 Business Strategies
      7.1.5 Recent Developments
7.2 GlaxoSmithKline plc
      7.2.1 Company Overview
      7.2.2 Financial Overview
      7.2.3 Product Portfolio
      7.2.4 Business Strategies
      7.2.5 Recent Developments
7.3 Merck & Co., Inc.
      7.3.1 Company Overview
      7.3.2 Financial Overview
      7.3.3 Product Portfolio
      7.3.4 Business Strategies
      7.3.5 Recent Developments
7.4 Novartis International AG
      7.4.1 Company Overview
      7.4.2 Financial Overview
      7.4.3 Product Portfolio
      7.4.4 Business Strategies
      7.4.5 Recent Developments
7.5 Pfizer, Inc.
      7.5.1 Company Overview
      7.5.2 Financial Overview
      7.5.3 Product Portfolio
      7.5.4 Business Strategies
      7.5.5 Recent Developments
7.6 Sanofi SA
      7.6.1 Company Overview
      7.6.2 Financial Overview
      7.6.3 Product Portfolio
      7.6.4 Business Strategies
      7.6.5 Recent Developments
7.7 Zoetis, Inc.
      7.7.1 Company Overview
      7.7.2 Financial Overview
      7.7.3 Product Portfolio
      7.7.4 Business Strategies
      7.7.5 Recent Developments
List of Tables
 
TABLE 1 Market Snapshot: U.S. Vaccine Market (2013 & 2020)
TABLE 2 U.S. Human Vaccine Market Revenue, by Type, 2012 – 2020 (USD Million)
TABLE 3 U.S. Human Vaccine Market Revenue, by Antigen, 2012 – 2020 (USD Million)
TABLE 4 Pricing Analysis: Hepatitis Vaccines
TABLE 5 Pricing Analysis: Influenza Vaccines
TABLE 6 Pricing Analysis: Meningococcal Vaccines
TABLE 7 Pricing Analysis: Pneumococcal Vaccines
TABLE 8 Pricing Analysis: Human Papillomavirus Vaccines (HPV)
TABLE 9 Pricing Analysis: Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV)
TABLE 10 Pricing Analysis: Other Vaccines
TABLE 11 U.S. Animal Vaccine Market Revenue, by Animal Type, 2012 – 2020 (USD Million)
TABLE 12 U.S. Companion Animal Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million)
TABLE 13 Pricing Analysis: Canine Vaccines
TABLE 14 Pricing Analysis: Feline Vaccines
TABLE 15 U.S. Livestock Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million)
TABLE 16 Pricing Analysis: Porcine Vaccines
TABLE 17 Pricing Analysis: Bovine Vaccines
TABLE 18 Pricing Analysis: Ovine Vaccines
TABLE 19 Pricing Analysis: Equine Vaccines
TABLE 20 Boehringer Ingelheim: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 21 GlaxoSmithKline plc: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 22 Merck & Co., Inc.: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 23 Novartis International AG: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 24 Pfizer, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 25 Sanofi SA: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 26 Zoetis, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million)
List of Figures
 
FIG. 1 U.S. Vaccine: Market Segmentation
FIG. 2 U.S. Human Vaccine Market, by Antigen, 2013 (USD Million)
FIG. 3 Major Steps: Vaccine Development and Commercialization
FIG. 4 U.S. Human Vaccine Market Share Analysis, by Key Players, 2013 (Value %)
FIG. 5 U.S. Animal Vaccine Market Share Analysis, by Key Players, 2013 (Value %)
FIG. 6 Comparative Analysis: U.S. Human Vaccine Market Revenue, by Antigen, 2013 & 2020 (Value %)
FIG. 7 U.S. Hepatitis Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 8 U.S. Influenza Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 9 U.S. Meningococcal Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 10 U.S. Pneumococcal Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 11 U.S. Human Papillomavirus Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 U.S. Combination Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 13 U.S. Other Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 14 Comparative Analysis: U.S. Animal Vaccine Market Revenue, by Animal Type, 2013 & 2020 (Value %)
FIG. 15 U.S. Canine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 16 U.S. Feline Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 17 U.S. Porcine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 18 U.S. Bovine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 19 U.S. Ovine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 20 U.S. Poultry Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 21 U.S. Equine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 22 Boehringer Ingelheim Vetmedica: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 23 GlaxoSmithKline plc: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 24 Merck & Co., Inc.: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 25 Novartis International AG: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 26 Pfizer, Inc.: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 27 Sanofi SA: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 28 Zoetis, Inc.: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

754

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved